Cancer of the liver
Conditions
Interventions
Case group:Transarterial chemoembolization with epirubicin-loaded CalliSpheres microspheres
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The estimated survival time of HCC patients over 18 years old is more than 3 months; 2. Patients with BCLC stage B and BCLC stage a who are unsuitable or unwilling to receive surgical or ablation treatment; 3. Patients with child Pugh grade A or B in liver function; 4. Patients with ECoG score 0 or 1; 5. Patients who have not received chemotherapy, ablation, transarterial embolization or chemoembolization; 6. Patients and / or family members agree to join the clinical trial and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with diffuse liver cancer; 2. Patients with liver tumor volume accounting for more than 50% of the whole liver; 3. Patients with invasion of large vessels (main portal vein, primary branch of portal vein, main trunk of hepatic vein and inferior vena cava) or extrahepatic metastasis; 4. Patients with severe liver dysfunction (including transaminase more than 5 times of normal upper limit, total bilirubin > 3.0 mg / dl, refractory ascites, uncontrollable hepatic encephalopathy or hepatorenal syndrome); 5. Patients with severe blood coagulation dysfunction, which can not be corrected; 6. Leukocyte count 2 mg / dL or creatinine clearance rate < 30 ml / min); 9. Patients with severe iodine contrast medium allergy; 10. Patients with cachexia or multiple organ failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival;serious adverse events;complete response rate;objective response rate; | — |
Countries
China
Contacts
Public ContactYumin Wu
Shenzhen Second People's Hospital
Outcome results
None listed